Adaptive Radiotherapy in Head and Neck Tumor Patients

Condition(s) studied

Investigational drug(s) / intervention(s)

Adaptive Radiotherapy: Adaptive Radiotherapy

image guided radiotherapy without online adaptation: image guided radiotherapy without online adaptation

Study summary

Most newly diagnosed oropharyngeal and hypopharyngeal cancers are treated with radiochemotherapy with curative intent. If the field-set UP margins are broad, the consequence may be that quality of life is impaired. The study group of Nutting et al. (2023) investigated this year whether dysphagia-optimized intensity-modulated radiotherapy can reduce the radiation dose to structures associated with dysphagia and aspiration and improve swallowing function compared to standard IMRT (Nutting C, Finneran L, Roe J, Petkar I, Rooney K, Hall E; DARS Triallist Group. Dysphagia-optimized intensity-modulated radiotherapy versus standard radiotherapy in patients with pharyngeal cancer - Authors' reply. Lancet Oncol. 2023 Oct;24(10):e398. doi: 10.1016/S1470-2045(23)00457-6. PMID: 37797636.) The study group concluded that the results suggest that dysphagia-optimized IMRT improves patient-reported swallowing function compared to standard IMRT. DO-IMRT should be considered the new standard of care for patients receiving radiotherapy for pharyngeal cancer, and ART could further improve outcomes.

Eligibility

Primary outcome measure(s)

• EORTC CTC AE Score — 2 months - 5 years
  quality of life, Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: November 27, 2017
• Dysphagia score — 2 months - 5 years
  Dysphagia score

Trial sites (1)

More University Hospital, Essen trials in Germany

Other trials for the same condition